SURVYR

NVO

Novo Nordisk A/S
$38.67
−$0.46 (1.18%)Oct 27 close
Healthcare CompareTechnicals
1M3M6M1Y2Y
-32%-19%-5%+8%+21%Oct 2025Oct 2026Apr 202652w low $35.12
NVOSPY
Wall St. Highest PT $61.45 (+58.9%) Wall St. Avg PT $44.85 (+16.0%)
$34$45$56$67$77POC $47Hi $61Avg $45
Underwater Drawdown %Max DD -43.7%Current -36.5%
0.0%-43.7%
Relative Strength vs SPY-36.8% vs SPYUnderperforming
+46%0%-46%
1W
−$0.68 (1.73%)
1M
−$0.13 (0.34%)
3M
−$11.65 (23.15%)
6M
−$1.98 (4.87%)
YTD
−$9.79 (20.20%)
1Y
−$11.71 (23.24%)

Chart

Loading live chart…

Ratings & dials

1m · 5m · 15m · 1h · 4h · 1D

Analyst & Morningstar ratings

Consensus · Targets · Morningstar
Wall Street analyst consensus
SellHoldStrong Buy
Hold
14 analysts · mean score 2.71
1 = Strong Buy · 5 = Sell
Strong Buy00%
Buy321%
Hold1071%
Underperform17%
Sell00%
Wall Street consensus
Analyst price targets
Current price$38.67
Average target$44.85
+$6.18 (+16.0%) upsideaverage target vs current price
CurrentAverageMedian
Low$39.53
Median$41.82
High$61.45
12-month Wall Street target range
Recent analyst rating changes · 30
Reiterated
2026-10-12 · BMO Capital reiterated Market Perform on NVO
Downgrade
2026-09-11 · Morgan Stanley downgraded NVO from Equal-Weight to Underweight
Downgrade
2026-03-02 · Goldman Sachs downgraded NVO from Buy to Neutral
Downgrade
2026-02-24 · JP Morgan downgraded NVO from Overweight to Neutral
Initiated
2026-01-09 · CICC started covering NVO at Outperform
Downgrade
2025-12-08 · Argus Research downgraded NVO from Buy to Hold
All analyst rating changes ›

Third-party ratings, not SURVYR.'s views.

Key stats & company

Market value$170.6B
P/E (last 12 months)9.4
P/E (next 12 months, estimated)11.2
52-week range$35.12 – $64.16
Revenue growth (latest quarter vs a year ago)+2.1%
Dividend yield4.59%
Analyst consensusHold (12)
Average analyst price target$44.85 (+16%)

What they do

Novo Nordisk A/S engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas.

Healthcare · Drug Manufacturers - General
Valuation and fundamentals

Valuation & fundamentals

Loading the valuation from SEC filings…

For information only · Important disclosures

Grades vs sector

No sector grades for NVO yet. Grades rank S&P 1500 stocks within their sector and refresh after each daily data run, so a stock outside that index or newly covered has none.

Systematic Models

Not held by any of our 7 live models right now.

Quality Growth
Outside this model's universe or screens
 Momentum Top 15
Outside this model's universe or screens
 Momentum Blend
Not in the current book
 New Highs Growth
Outside this model's universe or screens
 SURVYR. Barbell Momentum & T-Bill Shield
Outside this model's universe or screens
 SURVYR. Physical AI Grid & Power
Outside this model's universe or screens
 SURVYR. Long Book
Not in the current book

Earnings & events

NVO earningsNext report in 7 days
Next report · quarter Sep 2026
Wed Nov 4, 2026Before the open
EPS consensus$4.62 range $4.01–$5.28
Revenue consensus$73.7B 13 analysts
Last 4 quarters · EPS vs estimate
Aug 4, 2026$6.18est $4.98+24.0%Above estimates
May 5, 2026$6.63est $6.96−4.8%Below estimates
Feb 3, 2026$6.04est $5.90+2.3%Above estimates
Nov 5, 2025$4.50est $4.24+6.0%Above estimates

In line = within 1% of the estimate.

Source: Yahoo Finance · report time: Nasdaq earnings calendar · refreshed 2026-10-27 18:24:01 ET
24-1125-0225-0525-0825-1126-0226-0526-080.006.96
EstimateActual (beat)Actual (miss)

Quarterly revenue

QuarterRevenueYoY
2026-06-30$78.5B+2.1%
2026-03-31$96.8B–
2025-12-31$79.1B–
2025-09-30$75.0B–
2025-06-30$76.9B–

Recent dividends

2026-08-17: $0.579 · 2026-03-30: $1.275 · 2025-08-18: $0.584 · 2025-03-31: $1.099 · 2024-08-16: $0.513 · 2024-03-22: $0.930 · 2023-08-18: $0.442 · 2023-03-24: $0.595

News & catalysts

More news
Eli Lilly, IBD Stock Of The Day, Rides Foundayo, Medicare Bridge To Buy Point
Investor's Business Daily · Oct 19
Rating changes
Reiterated
2026-10-12 · BMO Capital reiterated Market Perform on NVO
Downgrade
2026-09-11 · Morgan Stanley downgraded NVO from Equal-Weight to Underweight
Downgrade
2026-03-02 · Goldman Sachs downgraded NVO from Buy to Neutral
Downgrade
2026-02-24 · JP Morgan downgraded NVO from Overweight to Neutral
Initiated
2026-01-09 · CICC started covering NVO at Outperform
Downgrade
2025-12-08 · Argus Research downgraded NVO from Buy to Hold

Third-party analyst actions, not SURVYR.'s views. All rating changes

Stats refreshed 2026-10-27 18:24:01 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Morning Brief (8 AM ET) & Market Close (4:30 PM ET), weekdays

Indexes, sectors, biggest movers, rates, top news, SURVYR. model changes and what's ahead. Free, two short emails each weekday.

Editions

Free. Not investment advice. Unsubscribe anytime.

SURVYR

Free to use. No card, no ads, no auto-renew.

Systematic research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app

How it worksOur promiseTermsPrivacyData statusSend feedback
Coteau 0.9 · Oct 21, 2026